29,648 Shares in AstraZeneca PLC $AZN Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 29,648 shares of the company’s stock, valued at approximately $2,072,000.

A number of other hedge funds and other institutional investors have also modified their holdings of AZN. Brighton Jones LLC grew its holdings in shares of AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares during the period. Nisa Investment Advisors LLC boosted its holdings in AstraZeneca by 115.4% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,400 shares of the company’s stock valued at $103,000 after purchasing an additional 750 shares during the last quarter. Xponance Inc. grew its stake in shares of AstraZeneca by 6.9% in the 1st quarter. Xponance Inc. now owns 3,465 shares of the company’s stock valued at $255,000 after buying an additional 224 shares during the period. New York State Common Retirement Fund increased its holdings in shares of AstraZeneca by 1.7% during the 1st quarter. New York State Common Retirement Fund now owns 135,357 shares of the company’s stock worth $9,949,000 after buying an additional 2,314 shares during the last quarter. Finally, Bleakley Financial Group LLC raised its position in shares of AstraZeneca by 14.8% during the 1st quarter. Bleakley Financial Group LLC now owns 69,761 shares of the company’s stock valued at $5,127,000 after buying an additional 8,986 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on AstraZeneca in a report on Monday, October 27th. They set a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Performance

NASDAQ AZN opened at $89.09 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The company has a market cap of $276.30 billion, a P/E ratio of 33.49, a P/E/G ratio of 1.52 and a beta of 0.34. The stock has a 50-day moving average of $81.73 and a two-hundred day moving average of $75.87. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $89.32.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the firm posted $2.08 earnings per share. The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.